Prospecto:information for the patient
Monovo 1 mg/g cream
furoate of mometasone
Read the entire prospect carefully before starting to use the medicationbecause it contains important information for you.
1.What Monovo is and for what it is used
2.What you need to knowbeforestarting touse Monovo
3.How to use Monovo
4.Possible adverse effects
5.Storage of Monovo
6.Contents of the package andadditional information
The active ingredient of Monovo is furoate mometasone.It belongs to a group of medications called corticosteroids (or steroids).
Topical corticosteroids are divided into four levels of potency:mild, moderate, potent, and very potent.Monovo is classified as a “potent corticosteroid”.
Monovo is indicated in adults, adolescents, and children aged 2 years and older, to relieve symptoms caused by certain inflammatory skin conditions such as psoriasis (except extensive plaque psoriasis) and atopic dermatitis.It is not a curative treatment for your condition, but it will help to relieve symptoms.
Do not use Monovo
Warnings and precautions
Consult your doctor or pharmacist before starting to use Monovo.
Children (under 2 years)
Monovo cream should not be used in children under 2 years.
Other medications and Monovo
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. This includes medications obtained without a prescription and other remedies or dietary supplements such as vitamins.
Consult your doctor before taking any medication.
Pregnancy and breastfeeding
Monovo contains alcohol cetoestearílico emulsionante, alcohol cetílico, and butylhydroxytoluene
This medication may cause local skin reactions (such as contact dermatitis) because it contains alcohol cetoestearílico emulsionante and alcohol cetílico.This medication may cause local skin reactions (such as contact dermatitis) or eye and mucous membrane irritation because it contains butylhydroxytoluene.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again. Your doctor must supervise the treatment regularly.
The recommended dose is:
Adults, including the elderly, adolescents, and children aged 2 years and older:
Adults, including the elderly:
Children (aged 2 years and older):
Administration form
Monovo is only for topical use (to be applied to the skin).
This medication is exclusively for external use.
If you use more Monovo than you should
If you forgot to use Monovo
If you interrupt treatment with Monovo
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. If your symptoms do not improve after using this medicine as instructed by your doctor, or if they worsen, consult your doctor.
The side effects reported in children and adults with the use of topical corticosteroids are:
Frequent: may affect up to 1 in 10 people
Include mild to moderate burning sensation in the application area, tingling/itching, pruritus, bacterial infections, abnormal skin sensations (paresthesia), cutaneous furuncles (furunculosis), skin thinning (skin atrophy).
Rare: may affect up to 1 in 100 people
Include irregular skin marks or striae, skin irritation, abnormal hair growth (hypertrichosis), skin color changes, perioral dermatitis, skin softening and whitening (maceration), contact allergic dermatitis, pus-filled vesicles on the face (papulosa rosacea dermatitis), inflammation (including acne-like reactions), purple or dark skin discoloration (ecchymosis), heat rash (miliaria), dryness, sensitization, folliculitis, and secondary infection.
Very rare: may affect up to 1 in 10,000 people
Widening of skin blood vessels or telangiectasia.
Unknown frequency: cannot be estimated from available data
Blurred vision.
The increased frequency of use, treatment of extensive skin areas, prolonged use, and use under dressings may increase the risk of side effects.
Corticosteroids can affect the normal production of steroids in the body. This is more likely to occur if high doses are used for a prolonged period.
Specifically, children treated with corticosteroid creams and ointments may absorb the product through the skin, which can cause a condition known as Cushing's syndrome, which produces several symptoms, such as moon face and weakness. Children receiving prolonged treatment may grow more slowly than other children. To avoid this, your doctor will prescribe the minimum dose of corticosteroids to control your symptoms effectively.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use,www.notificaRAM.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and the tube after “CAD”. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25 °C. Dispose of after 6 months of opening the tube.
Medications should not be thrown down the drains or in the trash. Deposit the containers and medications you no longer need at the SIGRE point of the pharmacy.Ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Monovo
The active principle is furoate of mometasone.
One gram of cream contains 1 mg of furoate of mometasone (0.1% furoate of mometasone)
The other components are:
Purified water, soft white paraffin (contains butylhydroxytoluene (E321) as an antioxidant), liquid paraffin, 2-methylpentane-2,4-diol, cetostearyl alcohol emulsifier (type A, contains disodium/potassium phosphate for pH adjustment), cetostearyl macrogol ether, cetilic alcohol, glycerol, citric acid, sodium citrate, xanthan gum.
Appearance of the product and packaging contents
Monovo is a white cream. The cream is packaged in PE/aluminum laminated tubes with a white plastic screw cap inside a cardboard box.
Packaging sizes: 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 50 g, 60 g, 70 g, 90 g, and 100 g of cream.
Only some packaging sizes may be commercially available.
Marketing authorization holder and manufacturer responsible
Almirall Hermal GmbH
Scholtzstraße 3
21465 Reinbek
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder
Almirall, S.A.
General Mitre, 151
08022 Barcelona - Spain
This medication is authorized in the member states of the European Economic Area with the following trade names:
Country | Trade name |
Austria | Monovo 1 mg/g Creme |
Germany | Monovo 1 mg/g Creme |
Ireland | Monovo 1 mg/g Cream |
Italy | Mundoson 1 mg/g Crema |
Luxembourg | Monovo 1 mg/g Creme |
Poland | Ivoxel |
Portugal | Ivoxel 1 mg/g Creme |
Spain | Monovo 1 mg/g Crema |
Netherlands | Monovo 1 mg/g Crème |
United Kingdom | Mometasone furoate 0.1% w/w Cream |
Last review date of this leaflet: May 2024
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
The average price of Monovo 1 mg/g crema in July, 2025 is around 5.81 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.